An exploratory assessment of the impact of a novel risk assessment test on breast cancer clinic waiting times and workflow: a discrete event simulation model
Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of Pi...
Uložené v:
| Vydané v: | BMC health services research Ročník 22; číslo 1; s. 1 - 9 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
29.10.2022
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1472-6963, 1472-6963 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic ‘overspill’ appointments generated (i.e. patients having to return to the clinic to complete their required investigations).
Methods
A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored.
Results
Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses.
Conclusion
The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. |
|---|---|
| AbstractList | Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic ‘overspill’ appointments generated (i.e. patients having to return to the clinic to complete their required investigations). Methods A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored. Results Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses. Conclusion The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. Abstract Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic ‘overspill’ appointments generated (i.e. patients having to return to the clinic to complete their required investigations). Methods A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored. Results Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses. Conclusion The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test - could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic 'overspill' appointments generated (i.e. patients having to return to the clinic to complete their required investigations). Methods A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored. Results Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses. Conclusion The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. Keywords: Breast neoplasms, Secondary Care Centres, Computer Simulation Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic ‘overspill’ appointments generated (i.e. patients having to return to the clinic to complete their required investigations). Methods A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored. Results Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses. Conclusion The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test - could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic 'overspill' appointments generated (i.e. patients having to return to the clinic to complete their required investigations).BACKGROUNDBreast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test - could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic 'overspill' appointments generated (i.e. patients having to return to the clinic to complete their required investigations).A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored.METHODSA simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored.Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses.RESULTSUnder standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses.The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred.CONCLUSIONThe findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test - could help to reduce unnecessary clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number of clinic 'overspill' appointments generated (i.e. patients having to return to the clinic to complete their required investigations). A simulation model was built to reflect the annual flow of patients through a single UK clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for delayed referral. A range of sensitivity analyses were conducted to explore the impact of key uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly clinics from the clinic schedule, were also explored. Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, > 98% of patients met the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one weekly low-capacity clinic [N = 10], and the results were robust to sensitivity analyses. The findings from this early analysis indicate that risk prediction tools could have the potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake of heightened pressures resulting from the COVID-19 pandemic. Further research is required to validate these findings with real world evidence; evaluate the broader clinical and economic impact of the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test and therefore not initially referred. |
| ArticleNumber | 1301 |
| Audience | Academic |
| Author | Shinkins, Bethany Frempong, Samuel N. Neal, Richard D. Smith, Alison F. Sharma, Nisha Hick, Louise |
| Author_xml | – sequence: 1 givenname: Alison F. surname: Smith fullname: Smith, Alison F. email: a.f.c.smith@leeds.ac.uk organization: Leeds Institute of Health Sciences (LIHS), University of Leeds, NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC), Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds – sequence: 2 givenname: Samuel N. surname: Frempong fullname: Frempong, Samuel N. organization: Leeds Institute of Health Sciences (LIHS), University of Leeds, NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC) – sequence: 3 givenname: Nisha surname: Sharma fullname: Sharma, Nisha organization: Leeds Teaching Hospitals NHS Trust (LTHT) – sequence: 4 givenname: Richard D. surname: Neal fullname: Neal, Richard D. organization: University of Exeter Medical School, University of Exeter – sequence: 5 givenname: Louise surname: Hick fullname: Hick, Louise organization: NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC), Leeds Teaching Hospitals NHS Trust (LTHT) – sequence: 6 givenname: Bethany surname: Shinkins fullname: Shinkins, Bethany organization: Leeds Institute of Health Sciences (LIHS), University of Leeds, NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC) |
| BookMark | eNp9kstu1DAUhiNUJNrCC7CyxIZNiu1cHLNAGlVcKlViA2vLsU-mnjr2YGdm6MPwrpzMFLVTocoL3_7_S87xf1achBigKN4yesFY137IjEtWlZTzknZt25T0RXHKasHLVrbVyaP1q-Is5xWlTHRcnBZ_FoHA77WPSU8x3RGdM-Q8QphIHMh0A8SNa232O01C3IInyeXbx8IJMt4H0ifQuDI6GEjEeBecITvtJheWZHIjZKKDJbuYbgcfdx8RaF02CSYgsJ1J2Y0bryeHsDFa8K-Ll4P2Gd7cz-fFzy-ff1x-K6-_f726XFyXpunqqWw1FSD6ivVWdtw0gwTTMNlrW1VGDGJoettIQQ2Fqsf-dHUreqibSjassgDVeXF14NqoV2qd3KjTnYraqf1BTEul0-SMB2XRLtpW91091IIJKXve0Vo00FjagkbWpwNrvelHsAbrStofQY9vgrtRy7hVsmWiqSgC3t8DUvy1wd6qEbsE3usAcZMVFyjC92QSpe-eSFdxkwK2alYJwaXo6INqqbEAF4aI3zUzVC0ErxuOsZlZF_9R4bAwOoNxGxyeHxm6g8GkmHOCQRk37R8Pjc4rRtWcTXXIpkKP2mdTzX_En1j_tedZU3UwZRSHJaSHYp9x_QVI6Pq6 |
| CitedBy_id | crossref_primary_10_1002_acm2_70252 crossref_primary_10_1080_01605682_2025_2557921 crossref_primary_10_1080_20476965_2024_2322451 |
| Cites_doi | 10.3390/ijerph182212262 10.1136/bmjopen-2021-053590 10.1007/s10278-018-0159-7 10.1371/journal.pone.0097459 10.1016/j.ejso.2020.03.068 10.1136/bmj.39258.688553.55 10.1017/S0266462315000598 10.1080/17477778.2018.1442155 10.1038/s41416-020-01182-z 10.1038/s41416-021-01465-z 10.1093/bjsopen/zraa023 10.1186/s12913-018-3456-4 10.1186/1471-2407-14-743 10.1016/j.cmpb.2007.05.006 10.1148/radiol.14141237 10.1093/jnci/djj210 10.1093/jnci/djz037 10.1054/brst.2001.0390 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7RV 7WY 7WZ 7X7 7XB 87Z 88C 88E 8FI 8FJ 8FK 8FL ABUWG AFKRA AZQEC BENPR BEZIV CCPQU DWQXO FRNLG FYUFA F~G GHDGH K60 K6~ K9. KB0 L.- M0C M0S M0T M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQBIZ PQBZA PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1186/s12913-022-08665-0 |
| DatabaseName | Springer Open Access Journals CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database ABI/INFORM Collection ABI/INFORM Global (PDF only) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ABI/INFORM Collection Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ABI/INFORM Collection (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Business Premium Collection ProQuest One Community College ProQuest Central Business Premium Collection (Alumni) Health Research Premium Collection ABI/INFORM Global (Corporate) Health Research Premium Collection (Alumni) ProQuest Business Collection (Alumni Edition) ProQuest Business Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ABI/INFORM Professional Advanced ABI/INFORM Global ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Business ProQuest One Business (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ABI/INFORM Global (Corporate) ProQuest Business Collection (Alumni Edition) ProQuest One Business ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ABI/INFORM Complete ProQuest Central ABI/INFORM Professional Advanced ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ABI/INFORM Complete (Alumni Edition) Business Premium Collection ABI/INFORM Global ABI/INFORM Global (Alumni Edition) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Business Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Business (Alumni) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Business Premium Collection (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1472-6963 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_d868766ab84f471799b280475e5d06ea PMC9617530 A724520229 10_1186_s12913_022_08665_0 |
| GeographicLocations | United Kingdom United Kingdom--UK England |
| GeographicLocations_xml | – name: United Kingdom – name: England – name: United Kingdom--UK |
| GrantInformation_xml | – fundername: CRUK CanTest Collaborative grantid: C8640/A23385; C8640/A23385 – fundername: NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC) – fundername: Innovate UK grantid: 105411; 105411; 105411; 105411; 105411; 105411 funderid: http://dx.doi.org/10.13039/501100006041 – fundername: ; – fundername: ; grantid: C8640/A23385; C8640/A23385 – fundername: ; grantid: 105411; 105411; 105411; 105411; 105411; 105411 |
| GroupedDBID | --- 0R~ 23N 2WC 44B 53G 5VS 6J9 6PF 7RV 7WY 7X7 88E 8FI 8FJ 8FL AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BEZIV BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 DWQXO E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FRNLG FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR INH INR ITC K60 K6~ KQ8 M0C M0T M1P M48 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQBIZ PQBZA PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION 3V. 7XB 8FK AZQEC K9. L.- PKEHL PQEST PQUKI Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c584t-6a07e7b31bd982c5f9ec519bad33c7f7f5bd5970c0e3b0868467be4539513dee3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000876266400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1472-6963 |
| IngestDate | Fri Oct 03 12:52:54 EDT 2025 Tue Nov 04 02:07:06 EST 2025 Thu Sep 04 16:57:08 EDT 2025 Tue Oct 07 05:52:09 EDT 2025 Tue Nov 11 10:15:07 EST 2025 Tue Nov 04 17:46:52 EST 2025 Tue Nov 18 22:20:26 EST 2025 Sat Nov 29 05:23:54 EST 2025 Sat Sep 06 07:27:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Secondary Care Centres Computer Simulation Breast neoplasms |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c584t-6a07e7b31bd982c5f9ec519bad33c7f7f5bd5970c0e3b0868467be4539513dee3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/d868766ab84f471799b280475e5d06ea |
| PQID | 2737729780 |
| PQPubID | 44821 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d868766ab84f471799b280475e5d06ea pubmedcentral_primary_oai_pubmedcentral_nih_gov_9617530 proquest_miscellaneous_2730314719 proquest_journals_2737729780 gale_infotracmisc_A724520229 gale_infotracacademiconefile_A724520229 crossref_citationtrail_10_1186_s12913_022_08665_0 crossref_primary_10_1186_s12913_022_08665_0 springer_journals_10_1186_s12913_022_08665_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-29 |
| PublicationDateYYYYMMDD | 2022-10-29 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMC health services research |
| PublicationTitleAbbrev | BMC Health Serv Res |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | 8665_CR11 8665_CR10 FC Coelli (8665_CR20) 2007; 87 R Savage (8665_CR12) 2022; 12 S Blacker (8665_CR27) 2020; 46 T Gathani (8665_CR24) 2021; 124 NK Stout (8665_CR19) 2006; 98 CI Lee (8665_CR18) 2015; 274 X Zhang (8665_CR13) 2018; 18 T Monks (8665_CR22) 2019; 13 P Sauven (8665_CR2) 2002; 11 S Potter (8665_CR1) 2007; 335 8665_CR23 T Amir (8665_CR21) 2019; 32 8665_CR26 8665_CR9 8665_CR25 8665_CR8 8665_CR7 8665_CR6 8665_CR5 JI Vázquez-Serrano (8665_CR14) 2021; 18 8665_CR4 8665_CR3 J Furzer (8665_CR17) 2020; 112 R Galvin (8665_CR29) 2014; 14 T Bessen (8665_CR15) 2015; 31 M Comas (8665_CR16) 2014; 9 S Ramzi (8665_CR28) 2021; 5 |
| References_xml | – ident: 8665_CR26 – volume: 18 start-page: 12262 issue: 22 year: 2021 ident: 8665_CR14 publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph182212262 – volume: 12 start-page: e053590 issue: 4 year: 2022 ident: 8665_CR12 publication-title: BMJ Open doi: 10.1136/bmjopen-2021-053590 – volume: 32 start-page: 221 issue: 2 year: 2019 ident: 8665_CR21 publication-title: J Digit Imaging doi: 10.1007/s10278-018-0159-7 – ident: 8665_CR11 – volume: 9 start-page: e97459 issue: 5 year: 2014 ident: 8665_CR16 publication-title: PLoS ONE doi: 10.1371/journal.pone.0097459 – volume: 46 start-page: e18 issue: 6 year: 2020 ident: 8665_CR27 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.03.068 – volume: 335 start-page: 288 issue: 7614 year: 2007 ident: 8665_CR1 publication-title: BMJ doi: 10.1136/bmj.39258.688553.55 – ident: 8665_CR6 – ident: 8665_CR4 – ident: 8665_CR8 – volume: 31 start-page: 281 issue: 5 year: 2015 ident: 8665_CR15 publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462315000598 – volume: 13 start-page: 55 issue: 1 year: 2019 ident: 8665_CR22 publication-title: J Simul doi: 10.1080/17477778.2018.1442155 – ident: 8665_CR23 – volume: 124 start-page: 710 issue: 4 year: 2021 ident: 8665_CR24 publication-title: Br J Cancer doi: 10.1038/s41416-020-01182-z – ident: 8665_CR25 doi: 10.1038/s41416-021-01465-z – ident: 8665_CR10 – volume: 5 start-page: zraa023 issue: 2 year: 2021 ident: 8665_CR28 publication-title: BJS open doi: 10.1093/bjsopen/zraa023 – volume: 18 start-page: 1 issue: 1 year: 2018 ident: 8665_CR13 publication-title: BMC Health Serv Res doi: 10.1186/s12913-018-3456-4 – volume: 14 start-page: 1 issue: 1 year: 2014 ident: 8665_CR29 publication-title: BMC Cancer doi: 10.1186/1471-2407-14-743 – volume: 87 start-page: 201 issue: 3 year: 2007 ident: 8665_CR20 publication-title: Comput Methods Programs Biomed doi: 10.1016/j.cmpb.2007.05.006 – ident: 8665_CR5 – volume: 274 start-page: 772 issue: 3 year: 2015 ident: 8665_CR18 publication-title: Radiology doi: 10.1148/radiol.14141237 – volume: 98 start-page: 774 issue: 11 year: 2006 ident: 8665_CR19 publication-title: JNCI: J Natl Cancer Inst doi: 10.1093/jnci/djj210 – ident: 8665_CR3 – ident: 8665_CR7 – ident: 8665_CR9 – volume: 112 start-page: 63 issue: 1 year: 2020 ident: 8665_CR17 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz037 – volume: 11 start-page: 262 issue: 3 year: 2002 ident: 8665_CR2 publication-title: The Breast doi: 10.1054/brst.2001.0390 |
| SSID | ssj0017827 |
| Score | 2.3749006 |
| Snippet | Background
Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test –... Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test -... Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools - such as the PinPoint test - could help to... Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint test –... Abstract Background Breast cancer clinics across the UK have long been struggling to cope with high demand. Novel risk prediction tools – such as the PinPoint... |
| SourceID | doaj pubmedcentral proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1 |
| SubjectTerms | Biopsy Breast cancer Breast neoplasms Clinics Computer Simulation Datasets Health Administration Health Informatics Health services Mammography Medical screening Medicine Medicine & Public Health Nursing Research Patients Public Health Risk assessment Secondary Care Centres Simulation Teaching hospitals Ultrasonic imaging |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVgywEJ8Y0IFGQkJA4QNYmd2OGCtqgVp1WFQOrNsh0HVlqSkmzbX9P_2hnHSQkVvXBM7Dh2Mh4_e2beEPI2tSVHprTYov2fM8ljEOU81oZlqc1ZJgz3ySbEaiWPj8ujcODWB7fKUSd6RV21Fs_I92CZRSAoZPLp5HeMWaPQuhpSaNwmO8hUxhdkZ_9gdfR1siPA-ifGUBlZ7PWwumE2A9iAJUj0Fiez5ciz9l_Xzdf9Jf8ymvq16PDB_47iIbkfUChdDmLziNxyzWNybzjCo0Nk0hNysWyo8y563hJP9UTiSduaAnCkQ4glXmnatGduQ9FT_c-KAGShvKEGfd-31KKMdXQIx6Tneo1O19Tnt6e6qSh6idWb9vwjNIjxwh1Aeuo5pmi__hUyjVGfvecp-X548O3zlzhkc4gtgJxtXOhEOGFYaqpSZjavS2cBPhpdMWZFLercVLC7SWzimIG_g8DIOJ4zwICsco49I4umbdxzQgGDWsNrwH7Sca5FaaSpNAY0iMRkhYtIOv5UZQPVOWbc2Ci_5ZGFGgRBgSAoLwgqicj76ZmTgejjxtr7KCtTTSTp9jfa7ocKc15VMAhRFNpI6KtA6j2TyYSL3OVVUjgdkXcoaQpVCXTP6hARAYNEUi61FGgWh7eWEdmd1QQVYOfFo7SpoIJ6dSVqEXkzFeOT6FbXuPbU18H0BSKFJsRMxmcjm5c065-ehrwskOUVWv8wzoarl__7y724ua8vyV0cEqKDrNwli2136l6RO_Zsu-6712F6XwKSOlkV priority: 102 providerName: ProQuest – databaseName: SpringerLINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQQQgJ8SgglrZokJA4QEQSJ7HT21JRcaFCvNSbZTsOrLQkVbJtf03_KzOOEwgFJDjueuzY8dj-nJn5hrGniS0zYkqLLNn_My6zCFU5j7ThaWJzngqT-WQT4uhIHh-X70JQWD96u48mSb9T-2Uti5c9nkyUiQAvTzGRtEV4Ub-Kx52k5fj-w-fJdoBnnhjDY35bb3YEeab-y_vxZR_JXwyl_vw5vP1_Pb_DbgW8CctBQe6yK67ZZtffBov6Nrs5fLeDIRzpHrtYNuC8X543v4OemDuhrQHRIgxxlfRLQ9OeuTWQe_rPgohesbwBQw7vG7CkWB0MMZhwrlfkaQ0-qT3opgJyDavX7fk-NkhBwh3iePDEUtCvvoX0YuBT9txnnw5ffzx4E4UUDpFFZLOJCh0LJwxPTFXK1OZ16SxiRqMrzq2oRZ2bCq80sY0dN_hyCA0Zl-UcgR-vnOMP2FbTNu4hAwSe1mQ1Aj7pskyL0khTaYpiELFJC7dgyTirygZ-c0qzsVb-niMLNcyDwnlQfh5UvGDPpzonA7vHX6VfkbJMksTM7f9ouy8qLHRV4SBEUWgjsa-C-PZMKuNM5C6v4sLpBXtGqqZo_8DuWR3CIHCQxMSlloJs4fjUcsF2Z5K47u28eFRWFfadXiEYpeuSkNjZJ1Mx1SRfusa1p16GchaIBJsQMyWfjWxe0qy-eu7xsiBqV2z9xajqPx7-5zf36N_Ed9gNGiJBhLTcZVub7tTtsWv2bLPqu8d-tX8HAmJQ9w priority: 102 providerName: Springer Nature |
| Title | An exploratory assessment of the impact of a novel risk assessment test on breast cancer clinic waiting times and workflow: a discrete event simulation model |
| URI | https://link.springer.com/article/10.1186/s12913-022-08665-0 https://www.proquest.com/docview/2737729780 https://www.proquest.com/docview/2730314719 https://pubmed.ncbi.nlm.nih.gov/PMC9617530 https://doaj.org/article/d868766ab84f471799b280475e5d06ea |
| Volume | 22 |
| WOSCitedRecordID | wos000876266400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ABI/INFORM Collection customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: 7WY dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/abicomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ABI/INFORM Global customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: M0C dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/abiglobal providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: M0T dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: 7RV dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Standard Collection customDbUrl: eissn: 1472-6963 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017827 issn: 1472-6963 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELZg8ICEED9Fx6gOCYkHiJbESWzz1k2b4GFVVcYoT5btOKJSSaa22_4a_lfunLQsTMALL5ZaO47tO9uf47vvGHudOJURU1rk6P4_4zKLUJXzyFieJi7nqbBZCDYhxmM5m6nJtVBfZBPW0gO3A7dfygInbGGszCpcSIVSNpVxJnKfl3HhAzRC1LM5THX3B7jviY2LjCz2V7irURQDPHjFRPAWxb1tKLD131yTb9pJ_nZZGvag44fsQQceYdQ2-hG75evH7H775Q1ah6In7MeoBh8s68IFOpgt9yY0FSDeg9Yzkn4ZqJtLvwAyML9eEPEn5tdgyWR9DY5UYwmtFyVcmTnZSkMISw-mLoGMu6pFc_UeKyQ33yUicQjUULCaf-8ChEEIuvOUfT4-Oj38EHVBGCKH2GQdFSYWXlie2FLJ1OWV8g5RnzUl505UosptiYeS2MWeWxxcwjPWZzlH6MZL7_kztlM3tX_OAKGjsyjFvJA-y4xQVtrSkB-CiG1a-AFLNjLRrmMop0AZCx1OKrLQrRw1ylEHOep4wN5unzlv-Tn-WvqARL0tSdza4Q_UON1pnP6Xxg3YG1IUTSsANs-ZzpEBO0lcWnok6DYb36oGbK9XEmeu62dvVE13K8dKI5ykA4-Q2NhX22x6kqzhat9chDIUdUAkWIXoqWivZ_2cev4tsIergshZsfZ3G2X-9fI_j9zu_xi5F-wedZy2_lTtsZ318sK_ZHfd5Xq-Wg7ZbTE9o_TLV0pnIqRyyO4cHI0n02GY4ZiexIchPcWcyceTCZWefjr7CZm5Us8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQQIJ8UYECgwSiANEdZ5OkBBaHlWrtisOi9SbsR0HVlqSkt12xY_hL_AbmXGSLaGitx44JnYc2xnPfI5nvmHsaWDymJjSfEPn_3GUxT6KcuIrHYWBSaJQ6NglmxDjcXZwkH9cY7_6WBhyq-x1olPURW3oH_kmmlkCgiLjbw6_-5Q1ik5X-xQarVjs2h9L3LLNX--8x-_7LAy3PkzebftdVgHfoLFd-KniwgodBbrIs9AkZW4NwhitiigyohRlogtE2dxwG2kE_GSgtY2TCLFIVFgbYbsX2EXi1SMXwn0-WZ1aoLUVfWBOlm7O0ZZS7gTc7nGilfP5wPi5HAGnLcFp78y_jmid5du6_r_N2Q12rcPYMGoXxU22Zqtb7Gr7gxLauKvb7OeoAuscEJ2fAagVRSnUJSAshjaAlK4UVPWxnQH54f9ZEWE6llegybN_AYZWUANtsCks1ZRcymFBQTagqgLIB66c1ctX2CBFQze4YQHHoAXz6bcujxq43ER32KdzmaG7bL2qK3uPASJso-MSkW1m41iJXGe6UBSuIbgOU-uxoBciaToid8onMpNuQ5elshU8iYInneBJ7rEXq2cOWxqTM2u_Jdlc1SQKcnejbr7ITqPJAgch0lTpDPsqiFhQhxmPRWKTgqdWeew5SbYkRYndM6qL98BBEuWYHAk69Me35h7bGNREBWeGxb10y07BzuWJaHvsyaqYniSnwcrWR64OJWcQATYhBmtqMLJhSTX96kjW85Q4bLH1l_3qO3n5v2fu_tl9fcwub0_29-Teznj3AbtCwyMcFOYbbH3RHNmH7JI5XkznzSOnWIB9Pu9V-RtkxbU2 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtQwELVQQRUS4lKoWChgJCQeIGoSO7HD23JZgYBVJS7qm2U7Dqy0OFU2bb-Gf2XGudBQQEI87nrs2PGsfWZn5gwhjxJbcGRKiyz6_zmTPAJVziJtWJrYjKXC8FBsQiyX8vCwODiTxR-i3QeXZJfTgCxNvt0_KqvuJy7z_Q3cUliVAAypGAnbIjDaL3IsGoT2-ofPox8B7j8xpMr8tt_kOgqs_efP5vPxkr84TcNdtLj2_6u4Tq72OJTOO8W5QS44v0O23_ee9h1ypfs_j3ZpSjfJ97mnLsTrBbc81SOjJ60rCiiSdvmW-ElTX5-4NcWw9bOCgGqh3VODgfAttahwDe1yM-mpXmEENg3F7qn2JcWQsWpdnz6DATF5uAF8TwPhFN2svvVlx2go5XOLfFq8-vjiddSXdogsIJ42ynUsnDAsMWUhU5tVhbOAJY0uGbOiElVmSjB1Yhs7ZuDlIEoyjmcMACErnWO7ZMvX3t0mFACpNbwCICgd51oURppSY3aDiE2auxlJhh1Wtuc9x_IbaxXsH5mrbh8U7IMK-6DiGXky9jnqWD_-Kv0cFWeURMbu8EXdfFH9AaBKWITIc20kzFUgD59JZcxF5rIyzp2ekceodgrPFZie1X16BCwSGbrUXKCPHJ5azMjeRBLOAzttHhRX9efRRgFIRTNKSJjsw7EZe2KMnXf1cZDBWgYigSHEROEnK5u2-NXXwEle5Ej5CqM_HdT-58P__Obu_Jv4A7J98HKh3r1Zvr1LLuNqEUWkxR7Zaptjd49csiftatPcD4fAD-rvXL8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+exploratory+assessment+of+the+impact+of+a+novel+risk+assessment+test+on+breast+cancer+clinic+waiting+times+and+workflow%3A+a+discrete+event+simulation+model&rft.jtitle=BMC+health+services+research&rft.au=Smith%2C+Alison+F.&rft.au=Frempong%2C+Samuel+N.&rft.au=Sharma%2C+Nisha&rft.au=Neal%2C+Richard+D.&rft.date=2022-10-29&rft.pub=BioMed+Central&rft.eissn=1472-6963&rft.volume=22&rft_id=info:doi/10.1186%2Fs12913-022-08665-0&rft.externalDocID=PMC9617530 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6963&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6963&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6963&client=summon |